RT Journal Article
SR Electronic
T1 Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.05.22276016
DO 10.1101/2022.06.05.22276016
A1 Assawakosri, Suvichada
A1 Kanokudom, Sitthichai
A1 Chansaenroj, Jira
A1 Suntronwong, Nungruthai
A1 Auphimai, Chompoonut
A1 Nilyanimit, Pornjarim
A1 Vichaiwattana, Preeyaporn
A1 Thongmee, Thanunrat
A1 Duangchinda, Thaneeya
A1 Chantima, Warangkana
A1 Pakchotanon, Pattarakul
A1 Srimuan, Donchida
A1 Thatsanatorn, Thaksaporn
A1 Klinfueng, Sirapa
A1 Sudhinaraset, Natthinee
A1 Wanlapakorn, Nasamon
A1 Mongkolsapaya, Juthathip
A1 Honsawek, Sittisak
A1 Poovorawan, Yong
YR 2022
UL http://medrxiv.org/content/early/2022/06/06/2022.06.05.22276016.abstract
AB Objectives The SARS-CoV-2 Omicron variant presents numerous mutations potentially able to evade neutralizing antibodies (NAbs) elicited by COVID-19 vaccines. Therefore, this study aimed to provide evidence on a heterologous booster strategy to overcome the waning immunity against Omicron variants.Methods Participants who completed Oxford/AstraZeneca (hereafter AZD1222) for 5-7 months were enrolled. The reactogenicity and persistence of immunogenicity in both humoral and cellular response after a homologous or heterologous booster with the AZD1222 and mRNA vaccines (BNT162B2, full or half-dose mRNA-1273) administered six months after primary vaccination were determined.Results Total 229 individuals enrolled, a waning of immunity was observed 5-7 months after the AZD1222-primed. Total RBD immunoglobulin (Ig) levels, anti-RBD IgG and focus reduction neutralization test against Omicron BA.1 and BA.2 and T cell response peaked 14-28 days after booster vaccination. Both the full and half dose of mRNA-1273 induced the highest response, followed by BNT162b2 and AZD1222. At 90 days, the persistence of immunogenicity was observed among all mRNA-boosted individuals. Adverse events were acceptable and well tolerated for all vaccines.Conclusions A heterologous mRNA booster provided a significantly superior boost of binding and NAbs levels against the Omicron variant compared to a homologous booster in individuals with AZD1222-primed vaccinations.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialTCTR20210910002Funding StatementThis work was supported by the Health Systems Research Institute (HSRI), National Research Council of Thailand (NRCT), the Center of Excellence in Clinical Virology, Chulalongkorn University, and King Chulalongkorn Memorial Hospital and was partially supported by the Second Century Fund (C2F), Chulalongkorn University. Thaneeya Duangchinda was supported by National Center for Genetic Engineering and Biotechnology (BIOTEC Platform No. P2051613).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study protocol was approved by the Institutional Review Board of the Faculty of Medicine of Chulalongkorn University (IRB numbers 690/64)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.